Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 1115-70-4 | Product Number: M2009
Metformin Hydrochloride
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 1,1-Dimethylbiguanide Hydrochloride
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 25G |
$78.00
|
15 | 1 | ≥100 |
|
| 100G |
$228.00
|
9 | 4 | ≥100 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | M2009 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__4H__1__1N__5·HCl = 165.63 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Hygroscopic |
| CAS RN | 1115-70-4 |
| Related CAS RN | 657-24-9 |
| Reaxys Registry Number | 3626131 |
| PubChem Substance ID | 160871506 |
| Merck Index (14) | 5938 |
| MDL Number | MFCD00012582 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 219.0 to 223.0 °C |
Properties (reference)
| Melting Point | 221 °C |
| Maximum Absorption Wavelength | 233(H2O) nm |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H320 : Causes eye irritation. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | DU1800000 |
Transport Information:
| HS Number | 2925.29.9000 |
Application
Bone research
References
- Metformin regulates bone marrow stromal cells to accelerate bone healing in diabetic mice
- The Differential Effect of Metformin on Osteocytes, Osteoblasts, and Osteoclasts
- Metformin Enhances Osteogenesis and Suppresses Adipogenesis of Human Chorionic Villous Mesenchymal Stem Cells
- Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status
- Effect of Metformin on Bone Marrow Progenitor Cell Differentiation: In Vivo and In Vitro Studies
Application
Quorum sensing research / Biofilm research
Reference
- Repurposing metformin as a quorum sensing inhibitor in Pseudomonas aeruginosa
Application
Mitophagy research
References
- Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53
Application
Activation of AMP-activated Protein Kinase (AMPK) by Metformin
Metformin hydrochloride, an oral biguanide antihyperglycemic agent, is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin lowers the blood glucose concentration without causing hypoglycemia, but the precise mechanism of action of metformin is not fully understood. However, it has been reported that metformin activates adenosine 5’-monophosphate-activated protein kinase (AMPK, a major cellular regulator of lipid and glucose metabolism) in hepatocytes. As a result, hepatic glucose production is decreased and skeletal myocyte glucose uptake is increased. Recently, some combination agents with other anti-diabetes agents (eg. sulfonylureas and thiazolidinediones) have been developed to treat type-2 diabetes. (The product is for research purpose only.)
References
- Role of AMP-activated protein kinase in mechanism of metformin action
- Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects with Type 2 Diabetes
- The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways
- The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism
- AMP-activated Protein Kinase is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells
- The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
- Cellular and molecular mechanisms of metformin: an overview
- The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide, or glimperide in plasma
Application
Metformin Shows an Antidiabetic Effect by Regulating Lipid Metabolism via AMPK-ACC Pathway
Reference
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.